Binimetinib methyl ester impurity

A validated LC-​MS​/MS assay for the simultaneous quantification of the FDA-​approved anticancer mixture (encorafenib and binimetinib)​: metabolic stability estimation
By Attwa, Mohamed W.; Darwish, Hany W.; Al-Shakliah, Nasser S.; Kadi, Adnan A.
From Molecules (2021), 26(9), 2717
 
A Validated LC-​MS​/MS Assay for the Simultaneous Quantification of the FDA-​Approved Anticancer Mixture (Encorafenib and Binimetinib)​: Metabolic Stability Estimation
By Attwa Mohamed W; Darwish Hany W; Al-Shakliah Nasser S; Kadi Adnan A; Attwa Mohamed W; Darwish Hany W
From Molecules (Basel, Switzerland) (2021), 26(9)

Binimetinib methyl ester impurity is chemically Methyl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate. Binimetinib methyl ester impurity is supplied with detailed characterization data compliant with regulatory guideline. Binimetinib methyl ester impurity can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Binimetinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.